Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Christopher M. Murphy appointed CFO effective May 11, 2026, bringing prior biotech, commercial, corporate development, and investment banking experience.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Christopher M. Murphy appointed CFO effective May 11, 2026, bringing prior biotech, commercial, corporate development, and investment banking experience
- Independent-contractor compensation includes $42,916.66 monthly fees, bonus opportunity up to 40% of annual fees, and $1,750,000 RSU grant
- CFO agreement permits termination at any time, with nine months’ fee continuation after qualifying termination without cause
- Change-of-control termination provides 12 months’ fees, prorated bonus payment, and full vesting of outstanding equity awards
- Owen Hughes appointed Class I director and received 11,250 RSUs vesting over three years subject to continued service
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.